接受免疫检查点抑制剂治疗的类风湿关节炎合并非小细胞肺癌患者的生存分析:一项观察性队列研究
该回顾性队列研究利用医疗保险索赔数据,比较了接受免疫检查点抑制剂(ICI)治疗的转移性非小细胞肺癌(mNSCLC)患者中,合并类风湿关节炎(RA)与不合并RA者的总生存期(OS)。共纳入2732例患者(RA组790例,非RA组1942例)。结果显示,在调整人口学特征和合并症后,两组OS无显著差异(风险比0.92,95%置信区间0.78-1.09)。
要点
- 合并RA的mNSCLC患者接受ICI治疗后,总生存期与不合并RA者无显著差异(HR 0.92,95%CI 0.78-1.09)。
- RA组女性更多、合并症更多,且ICI启动前使用类固醇的比例更高(63% vs 45%)。
- ICI启动前类固醇剂量与更差OS相关,但排除使用地塞米松的患者后该关联不再显著。
核心结论
- 在控制人口学特征和合并症后,接受ICI治疗的合并RA的mNSCLC患者与不合并RA的患者相比,总生存期无差异。
- 排除使用地塞米松的患者后,类固醇剂量与更差OS无关。
研究设计与样本
- 回顾性队列研究,使用医疗保险索赔数据。
- 纳入年龄≥66岁、诊断为肺及支气管恶性肿瘤、并于2015年3月4日至2019年4月11日期间启动纳武利尤单抗、帕博利珠单抗或阿替利珠单抗治疗的患者。
- 采用Kaplan-Meier法和调整Cox比例风险模型进行生存分析。
- 分析队列共2732例mNSCLC患者,其中RA组790例,非RA组1942例。
主要发现
- RA组女性比例更高,合并症更多。
- RA组ICI启动前使用类固醇的比例高于非RA组(63% vs 45%),但使用地塞米松的比例两组相同(27% vs 28%)。
- Kaplan-Meier生存曲线显示RA组与非RA组OS无差异(log-rank P = 0.08)。
- 调整模型显示RA与非RA组OS无差异(风险比0.92,95%置信区间0.78-1.09)。
- 男性、合并症更多、ICI启动前类固醇剂量与更差OS相关;排除使用基线地塞米松的患者后,ICI启动前类固醇剂量与更差OS的关联不再显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to compare overall survival (OS) in immune checkpoint inhibitor (ICI)-treated patients with metastatic non-small cell lung cancer (mNSCLC) with pre-existing rheumatoid arthritis (RA) versus those without RA. METHODS: A retrospective cohort study using Medicare claims data was performed. Participants included patients aged ≥66 years with a diagnosis of a malignant neoplasm of lung and bronchus who initiated nivolumab, pembrolizumab, or atezolizumab between March 4, 2015 and April 11, 2019, which is after the US Food and Drug Administration (FDA) approval of ICIs for mNSCLC but before the first FDA approval for stage III disease. Survival analysis using Kaplan-Meier and adjusted Cox proportional hazard models was performed. RESULTS: A total of 2,732 people with mNSCLC (N = 790 RA and N = 1,942 non-RA) were in the analytic cohort. Patients with RA were more likely to be female and had more comorbidities than patients without RA. Patients with RA were more likely to be taking steroids than those without RA (63% vs 45%) but equally likely to be taking dexamethasone, usually prescribed for cancer palliation, specifically (27% vs 28%) before ICI initiation. There was no difference in OS between the RA and non-RA NSCLC Kaplan-Meier survival curves (log-rank P = 0.08) and in adjusted models (hazard ratio 0.92, 95% confidence interval 0.78-1.09). Male sex, having more comorbidities, and steroid dose before ICI initiation were associated with worse OS. In a sensitivity analysis omitting patients receiving baseline dexamethasone, steroid dose before ICI initiation was no longer associated with worse OS. CONCLUSION: After controlling for demographics and comorbid conditions, ICI-treated patients with RA with mNSCLC had no difference in OS compared with patients without RA. After excluding patients receiving dexamethasone, steroid dose was not associated with worse OS.
引用
- Jannat-Khah DP, Xie F, Saxena A, et al. Survival in Immune Checkpoint Inhibitor-Treated Patients With Rheumatoid Arthritis and Non-Small Cell Lung Cancer: An Observational Cohort Study. Arthritis Care Res (Hoboken). 2025. PMID: 40289860. doi:10.1002/acr.25561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。